RT Journal Article
SR Electronic
T1 Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.06.20123414
DO 10.1101/2020.06.06.20123414
A1 Takahashi, Takehiro
A1 Wong, Patrick
A1 Ellingson, Mallory K.
A1 Lucas, Carolina
A1 Klein, Jon
A1 Israelow, Benjamin
A1 Silva, Julio
A1 Oh, Ji Eun
A1 Mao, Tianyang
A1 Tokuyama, Maria
A1 Lu, Peiwen
A1 Venkataraman, Arvind
A1 Park, Annsea
A1 Liu, Feimei
A1 Meir, Amit
A1 Sun, Jonathan
A1 Wang, Eric Y.
A1 Wyllie, Anne L.
A1 Vogels, Chantal B.F.
A1 Earnest, Rebecca
A1 Lapidus, Sarah
A1 Ott, Isabel M.
A1 Moore, Adam J.
A1 Casanovas-Massana, Arnau
A1 Cruz, Charles Dela
A1 Fournier, John B.
A1 Odio, Camila D.
A1 Farhadian, Shelli
A1 Grubaugh, Nathan D.
A1 Schulz, Wade L.
A1 Ko, Albert I.
A1 Ring, Aaron M.
A1 Omer, Saad B.
A1 Iwasaki, Akiko
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/06/26/2020.06.06.20123414.abstract
AB A growing body of evidence indicates sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19)1-4. However, whether immune responses against SARS-CoV-2 differ between sexes, and whether such differences explain male susceptibility to COVID-19, is currently unknown. In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients. By focusing our analysis on patients with mild to moderate disease who had not received immunomodulatory medications, our results revealed that male patients had higher plasma levels of innate immune cytokines and chemokines including IL-8, IL-18, and CCL5, along with more robust induction of non-classical monocytes. In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age. Importantly, we found that a poor T cell response negatively correlated with patients’ age and was predictive of worse disease outcome in male patients, but not in female patients. Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients. These findings reveal a possible explanation underlying observed sex biases in COVID-19, and provide important basis for the development of sex-based approach to the treatment and care of men and women with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWomens Health Research at Yale Pilot Project Program; Fast Grant from Emergent Ventures at the Mercatus Center; Mathers Foundation; and the Ludwig Family Foundation. A.I. is an Investigator of the Howard Hughes Medical Institute. CBFV is supported by NWO Rubicon 019.181EN.004. AM is supported by NIH grant R37AI041699.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University Human Investigation CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll non PHI data in the manuscript will be made available upon request.